ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
To construct the statins Lipitor and Crestor, the antibiotic Zyvox, and several other drugs, chemists use the chiral building block 3-hydroxy-γ-butyrolactone (3HBL). But making this specialty chemical requires hazardous processing conditions and an expensive catalyst, which is why it costs about $450 per kg. To remedy that situation, MIT’s Kristala Jones Prather and colleagues created a biosynthetic route to 3HBL and its hydrolyzed form, 3,4-dihydroxybutyric acid, starting from glucose and glycolate or glucose alone (Nat. Commun., DOI: 10.1038/ncomms2418). Prather’s team took an existing enzymatic pathway used to make 3-hydroxybutyrate and 3-hydroxyvalerate and reengineered it to make the more structurally diverse 3-hydroxyacids. The key enzyme is a thiolase that catalyzes a C–C bond-forming Claisen condensation. The researchers acknowledge the pathway will need to be optimized if it’s going to compete with the current industrial process for making these building blocks. Even so, they note that it’s a promising demonstration of an engineered pathway that relies on C–C bond-forming reactions.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter